Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardization

References

• Hourigan CS, Gale RP, Gormley NJ, et al. Measurable residual disease testing in acute myeloid leukaemia. Leukemia. 2017;31:1482–1490.
   PubMed Web of Science ®Google Scholar
• Ommen HB. Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies. Ther Adv Hematol. 2016;7:3–16.
   PubMed Web of Science ®Google Scholar
• Buccisano F, Hourigan CS, Walter RB. The prognostic significance of measurable (“minimal”) residual disease in acute myeloid leukemia. Curr Hematol Malig Rep. 2017;12:547–556.
   PubMed Web of Science ®Google Scholar
• Freeman SD, Virgo P, Couzens S, et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol. 2013;31:4123–4131.
   PubMed Web of Science ®Google Scholar
• Freeman SD, Hills RK, Virgo P, et al. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. J Clin Oncol. 2018;36:1486–1497.
   PubMed Web of Science ®Google Scholar
• Loken MR, Alonzo TA, Pardo L, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from children’s oncology group. Blood. 2012;120:1581–1588.
   PubMed Web of Science ®Google Scholar
• Terwijn M, van Putten WLJ, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013;31:3889–3897.
   PubMed Web of Science ®Google Scholar
• Jaso JM, Wang SA, Jorgensen JL, et al. Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future. Bone Marrow Transplant. 2014;49:1129–1138.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Freeman SD. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”? Blood. 2014;124:3345–3355.
   PubMed Web of Science ®Google Scholar
• Buckley SA, Wood BL, Othus M, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017;102:865–873.
   PubMed Web of Science ®Google Scholar
• San Miguel JF. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood. 2001;98:1746–1751.
   PubMed Web of Science ®Google Scholar
• Venditti A, Buccisano F, Del Poeta G, et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood. 2000;96:3948–3952.
   PubMed Web of Science ®Google Scholar
• Kern W, Voskova D, Schoch C, et al. Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia. Haematologica. 2004;89:528–540.
   PubMed Web of Science ®Google Scholar
• Feller N, van der Pol MA, van Stijn A, et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leuk Off J Leuk Soc Am Leuk Res Fund, UK. 2004;18:1380–1390.
   PubMed Web of Science ®Google Scholar
• Sievers EL, Lange BJ, Alonzo TA, et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective children’s cancer group study of 252 patients with acute myeloid leukemia. Blood. 2003;101:3398–3406.
   PubMed Web of Science ®Google Scholar
• Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: consensus document from European leukemianet MRD working party. Blood. 2018;131:1275–1291.
   PubMed Web of Science ®Google Scholar
• Walter RB, Gyurkocza B, Storer BE, et al. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia. 2015;29:137–144.
   PubMed Web of Science ®Google Scholar
• Walter RB, Buckley SA, Pagel JM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 2013;122:1813–1821.
   PubMed Web of Science ®Google Scholar
• Al-Mawali A, Gillis D, Lewis I. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse. Cytometry B Clin Cytom. 2009;76:91–101.
   PubMed Web of Science ®Google Scholar
• Ossenkoppele G, Schuurhuis GJ. MRD in AML: does it already guide therapy decision-making? hematol. Am Soc Hematol Educ Progr. 2016;2016:356–365.
   PubMedGoogle Scholar
• Chang Y-J, Wang Y, Liu Y-R, et al. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol. 2017;10:134.
   PubMed Web of Science ®Google Scholar
• Buccisano F, Maurillo L, Piciocchi A, et al. Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia. Bone Marrow Transplant. 2017;52:473–475.
   PubMed Web of Science ®Google Scholar
• Johansson U, Bloxham D, Couzens S, et al. Guidelines on the use of multicolour flow cytometry in the diagnosis of haematological neoplasms. British committee for standards in haematology. Br J Haematol. 2014;165:455–488.
   PubMed Web of Science ®Google Scholar
• Cloos J, Harris JR, Janssen JJWM, et al. Comprehensive protocol to sample and process bone marrow for measuring measurable residual disease and leukemic stem cells in acute myeloid leukemia. J Vis Exp. 2018;(133). doi:10.3791/56386. Epub 2018 Mar 5.
   PubMed Web of Science ®Google Scholar
• Maurillo L, Buccisano F, Spagnoli A, et al. Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. Haematologica. 2007;92:605–611.
   Google Scholar
• Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJM, et al. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia. Leukemia. 2016;30:708–715.
   PubMed Web of Science ®Google Scholar
• Loken MR, Chu S-C, Fritschle W, et al. Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses. Cytometry B Clin Cytom. 2009;76:27–36.
   PubMed Web of Science ®Google Scholar
• Delgado JA, Guillén-Grima F, Moreno C, et al. A simple flow-cytometry method to evaluate peripheral blood contamination of bone marrow aspirates. J Immunol Methods. 2017;442:54–58.
   PubMed Web of Science ®Google Scholar
• Brooimans RA, Kraan J, van Putten W, et al. Flow cytometric differential of leukocyte populations in normal bone marrow: influence of peripheral blood contamination. Cytometry B Clin Cytom. 2009;76:18–26.
   PubMedGoogle Scholar
• Aldawood AM, Kinkade Z, Rosado FG, et al. A novel method to Assess bone marrow purity is useful in determining blast percentage by flow cytometry in acute myeloid leukemia and myelodysplasia. Ann Hematol Oncol. 2015;2:1038.
   PubMedGoogle Scholar
• Nombela-Arrieta C, Manz M. Quantification and three-dimensional microanatomical organization of the bone marrow. Blood Adv. 2017;1:407–416.
   PubMed Web of Science ®Google Scholar
• Terwijn M, Kelder A, Snel AN, et al. Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia. Int J Lab Hematol. 2012;34:432–441.
   PubMed Web of Science ®Google Scholar
• Wood BL. Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. Cytometry B Clin Cytom [Internet]. 2016 [cited 2018 Oct 30];90:47–53.
   PubMed Web of Science ®Google Scholar
• Mangalik A, Robinson WA, Drebing C, et al. Liquid storage of bone marrow. Exp Hematol. 1979;7(Suppl 5):76–94.
   PubMedGoogle Scholar
• Lipton J, Jamal N, Messner H. Extended duration between harvest and re-infusion of human bone marrow stored at room temperature. Bone Marrow Transplant. 1997;20:785–786.
   PubMed Web of Science ®Google Scholar
• Fry LJ, Giner SQ, Gomez SG, et al. Avoiding room temperature storage and delayed cryopreservation provide better postthaw potency in hematopoietic progenitor cell grafts. Transfusion. 2013;53:1834–1842.
   PubMed Web of Science ®Google Scholar
• Hahn S, Sireis W, Hourfar K, et al. Effects of storage temperature on hematopoietic stability and microbial safety of BM aspirates. Bone Marrow Transplant. 2014;49:338–348.
   PubMed Web of Science ®Google Scholar
• Zeijlemaker W, Gratama JW, Schuurhuis GJ. Tumor heterogeneity makes AML a “moving target” for detection of residual disease. Cytometry B Clin Cytom. 2014;86:3–14.
   PubMed Web of Science ®Google Scholar
• Bachas C, Schuurhuis GJ, Assaraf YG, et al. The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. Leukemia. 2012;26:1313–1320.
   PubMed Web of Science ®Google Scholar
• Wouters R, Cucchi D, Kaspers GJL, et al. Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design. Expert Rev Hematol. 2014;7:791–805.
   PubMed Web of Science ®Google Scholar
• Wood B, Jevremovic D, Béné MC, et al. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part V - assay performance criteria. Cytometry B Clin Cytom [Internet]. 2013 [cited 2018 Oct 30];84:315–323.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Jordan CT. Therapeutic targeting of acute myeloid leukemia stem cells. Blood. 2017;129:1627–1635.
   PubMed Web of Science ®Google Scholar
• Sarry J, Murphy K, Perry R, et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2R γ c-deficient mice. J Clin Invest. 2011;121:384–395.
   Google Scholar
• Taussig DC, Vargaftig J, Miraki-Moud F, et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood. 2010;115:1976–1984.
   PubMed Web of Science ®Google Scholar
• Terwijn M, Zeijlemaker W, Kelder A, et al. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS One. 2014;9:e107587.
   PubMed Web of Science ®Google Scholar
• van Rhenen A, Feller N, Kelder A, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res. 2005;11:6520–6527.
   PubMed Web of Science ®Google Scholar
• Ng SWK, Mitchell A, Kennedy JA, et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016;540:433–437.
   PubMed Web of Science ®Google Scholar
• Costello RT, Mallet F, Gaugler B, et al. Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res. 2000;60:4403–4411.
   PubMed Web of Science ®Google Scholar
• Ishikawa F, Yoshida S, Saito Y, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007;25:1315–1321.
   PubMed Web of Science ®Google Scholar
• Gerber JM, Smith BD, Ngwang B, et al. A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood. 2012;119:3571–3577.
   PubMed Web of Science ®Google Scholar
• Witte KE, Ahlers J, Schäfer I, et al. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia. Pediatr Hematol Oncol. 2011;28:91–99.
   PubMed Web of Science ®Google Scholar
• Zeijlemaker W, Kelder A, Wouters R, et al. Absence of leukaemic CD34+cells in acute myeloid leukaemia is of high prognostic value: A longstanding controversy deciphered. Br J Haematol. 2015;171:227–238.
   PubMed Web of Science ®Google Scholar
• Ran D, Schubert M, Taubert I, et al. Heterogeneity of leukemia stem cell candidates at diagnosis of acute myeloid leukemia and their clinical relevance. Exp Hematol. 2012;40:155–165.
   PubMed Web of Science ®Google Scholar
• Bradbury C, Houlton AE, Akiki S, et al. Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia. Leukemia. 2015;29:988–991.
   PubMed Web of Science ®Google Scholar
• Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJM, et al. A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia. Leukemia. 2016;30:439–446.
   PubMed Web of Science ®Google Scholar
• Löwenberg B, Pabst T, Maertens J, et al. Therapeutic value of clofarabine in younger and middle-aged (18–65 years) adults with newly diagnosed AML. Blood. 2017;129:1636–1645.
   PubMed Web of Science ®Google Scholar
• Stein EM, Paczolt E. Epigenetic modifiers in AML: a closer look at enasidenib, ivosidenib, pracinostat, vorinostat, pinometostat, and lsd1 inhibitors. In: Treatment in clinical trials. Nov 28, 2017. Available from: htpps://docs.google.com/document/d/1q6hTiyhpR0cJb-W8GQo-cUKFwhNCoqZCe0brAj4z_Q/edit [Last modified: July 26 2018]
   Google Scholar
• Kungulovski G, Nunna S, Thomas M, et al. Targeted epigenome editing of an endogenous locus with chromatin modifiers is not stably maintained. Epigenetics Chromatin. 2015;8:12.
   PubMed Web of Science ®Google Scholar
• Amir ED, Davis KL, Tadmor MD, et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat Biotechnol. 2013;31:545–552.
   PubMed Web of Science ®Google Scholar
• Qiu P, Simonds EF, Bendall SC, et al. Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat Biotechnol. 2011;29:886–891.
   PubMed Web of Science ®Google Scholar
• Van Gassen S, Callebaut B, Van Helden MJ, et al. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytom Part A. 2015;87:636–645.
   PubMedGoogle Scholar
• Weber LM, Robinson MD. Comparison of clustering methods for high-dimensional single-cell flow and mass cytometry data. Cytometry A. 2016;89:1084–1096.
   PubMedGoogle Scholar
• Ivey A, Hills RK, Simpson MA, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374:422–433.
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Song G, Shurtleff S, et al. Universal monitoring of minimal residual disease in acute myeloid leukemia. JCI Insight. 2018;3. doi:10.1172/jci.insight.98561 [Epub ahead of print].
   Web of Science ®Google Scholar
• Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378:1189–1199.
   PubMed Web of Science ®Google Scholar